Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1528-1167.2008.01580_6.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent Incarceration and HIV Risk Among Women Who Use Heroin.
JAMA Netw Open
January 2025
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Importance: Women who use heroin in sub-Saharan Africa face elevated HIV risk linked to structural vulnerability including frequent incarceration. However, little is known about the association between incarceration and drug use and HIV outcomes among women who use heroin in Africa.
Objective: To estimate associations between incarceration and adverse HIV-related and drug use-related outcomes among women who used heroin.
The Long-Term Treatment of Drug-Resistant Migraine with the Modified Atkins Ketogenic Diet: A Single-Center, Retrospective Study.
Nutrients
December 2024
Nephrology, Dialysis and Transplantation Unit, Department of Medicine, Azienda Ospedale-Università di Padova, 35128 Padua, Italy.
Despite advances in pharmacological therapies, migraine patients are often drug resistant. Further therapeutic options in this field are, therefore, desirable. Recent studies have highlighted the efficacy of ketogenic diet (KD) on improving migraine, but data on their long-term efficacy and safety are lacking.
View Article and Find Full Text PDF[Micronutrients intake in patients with refractory epilepsy with ketogenic diet treatment].
Andes Pediatr
October 2024
Facultad de Medicina, Departamento de Gastroenterología y Nutrición Pediátrica, Pontificia Universidad Católica de Chile, Santiago, Chile.
Unlabelled: The Ketogenic Diet (KD) is a non-pharmacological strategy for drug-resistant epilepsy (DRE) and inborn errors of metabolism (Glut-1 deficiency) management. KD is characterized by being restrictive, affecting micronutrient intake. There are different modalities of KD in which food intake and nutritional deficiencies vary.
View Article and Find Full Text PDFComparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
J Clin Oncol
January 2025
Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Article Synopsis
- CheckMate 204 study found that the combination of nivolumab and ipilimumab resulted in high intracranial objective response rates (icORRs) for patients with melanoma brain metastases (MBMs), prompting a need for standardized response criteria.
- Different assessment criteria (like mRECIST and volumetric measurements) showed higher icORRs and stronger correlations with progression-free survival (icPFS) and overall survival (OS) compared to RANO-BM and RECIST.
- The analysis suggests that mRECIST and volumetric criteria are reliable scales for future MBM trials, and response can be effectively measured even in patients with small lesions (<10 mm).
Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer.
Front Cardiovasc Med
December 2024
Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patients with ≥1 echocardiogram post-osimertinib between 2007 and 2022 was performed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!